102 results
DEFA14A
AIM
AIM ImmunoTech Inc
20 Nov 23
Additional proxy soliciting materials
7:30am
’ leadership, AIM has secured government-funded clinical trials for its lead product, Ampligen. Equels 496:14-24, 500:24-501:12; JX1241; see also Equels 499 … life sciences industry organization—and has held leadership roles at major industry players like Merck, GlaxoSmithKline, and Bayer. JX0678.0002; Bryan
DEFC14A
AIM
AIM ImmunoTech Inc
6 Nov 23
Proxy in contested solicitation
9:09am
and the board leadership structure to ensure the interests of the Company and its stockholders are best served.
Currently, the independent Chairman … , Committee Chair
Dr. William M. Mitchell
Nancy K. Bryan (since March 28, 2023)
Board Role in Risk Oversight
The Board evaluates its leadership
DEFC14A
jy4l1qv2mq5eke9g6 ph
1 Nov 23
Proxy in contested solicitation
5:01pm
PREC14A
p4ug agltbkpf
13 Oct 23
Preliminary proxy with contested solicitation
4:57pm
PREC14A
qww83tjnj13jd
10 Oct 23
Preliminary proxy with contested solicitation
9:00am
DFAN14A
7q2y9i86b58mn q5h9
28 Aug 23
Additional proxy materials by non-management
12:52pm
8-K
EX-99.1
8d4gfk qlmw
30 Mar 23
Departure of Directors or Certain Officers
8:50am
8-K
3ptymhtjcp8uh21g0
30 Mar 23
Departure of Directors or Certain Officers
8:50am
DEFA14A
9nsmqutu2
26 Oct 22
Additional proxy soliciting materials
5:19pm
DFAN14A
l8lfc5a9425lr
19 Oct 22
Additional proxy materials by non-management
3:26pm
DEFC14A
b5bv2lagu
28 Sep 22
Proxy in contested solicitation
5:09pm
PRRN14A
52y 9v5frwwv
23 Sep 22
Revised preliminary proxy statement filed by non-management
4:59pm